Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - NCCTG-N0026
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19) Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - AFT-19
Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687
Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance) Al-Refaie, Waddah B. , Decker, Paul A. , Pisters, Peter W.T. ... - SSO - Ann. Surg. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Older Adult - Z901101
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849
ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0776
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - A031501
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305 Armer, Jane M , Liu, Heshan , Oliveri, Jill , Seisler, Drew , tbd ... - ASCO CSS - J. Clin. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - CALGB-70305
Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors Arnold, Kristen , Andridge, Rebecca , Logan, Amanda , Yee, Lisa ... - EB - FASEB J - 2015 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - NCT01478477
Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N0993
Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance]) Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0148
A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7 Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C7
Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA Barton, D. L. , Soori, G. S. , Bauer, B. , Sloan, J. , Johnson, P. A. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA
A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA Barton, D. L. , Wos, E. , Qin, R. , Mattar, B. , Green, N. , Lanier, K. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA
Adiponectin: A novel biomarker for cancer- related fatigue?; NCCTG study N07C2 (Alliance) Barton, D. , Liu, H. , Tan, A. , Sloan, J. ... - MASCC / ISOO - Support Care Cancer - 2013 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N07C2
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance) Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML) Becker, H. , Marcucci, G. , Maharry, K. , Margeson, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - - Haematologica - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials Beutler, A. S. , Kulkarni, A. , Kanwar, R. , Qin, R. ... - AACR - AACR 2013 Annual Meeting - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - N08C1 , N08CA
Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance) Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance) Bhongsatiern, Jiraganya , Carbonetto, P. , Chua, Katherina C. ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502
Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance) Bill, Marius , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols Bill, Marius , Mrózek, K , Kohlschmidt, J. , Nicolet, D. ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , CALGB-9665
A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance) Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , C9665 , CALGB-20202
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105 Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-10503
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904
Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 Bogart, Jeffrey , Wang, Xiaofei , Masters, Gregory , Zhu, Han ... - ESMO - Ann Oncol - 2019 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-30610
Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153
Improving standards of patient reported outcomes analysis: developing a consensus taxonomy of key research objectives – a SISAQOL initiative Bottomley, Andrew , Pe, Madeline , Sloan, Jeff , Basch, Ethan ... - ISOQOL - Qual Life Res - 2018 Abstract - No-Endpoint Endpoint - Other Analysis - Health Outcome -
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071 Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance). Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - - Ann. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Neuro-Onc - A071401
Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma. Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-85-72-51
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases. Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041) Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633 Capelletti, M. , Wang, X. F. , Gu, L. , Graziano, S. L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9633
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - C40601
Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392
Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203) Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance) Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - Clinical Pharmacology & Therapeutics - 2018 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40101 , CALGB-40502
Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9831 , NSABP B-31
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831
Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer. Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52 Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
Acute Myeloid Leukemia (AML) with 9q aberrations occuring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB) Corbacioglu, A. , Frohling, S. , Paschka, P. , Marcucci, G. ... - ASH - Blood - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC) Cuffe, S. , Ezzalfani, M. , Bourredjem, A. , Graziano, S. L. ... - Chicago MSTO - - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC). Cuffe, S. , Graziano, S. , Bourredjem, A. , Pignon, J. P. ... - - J Thorac Oncol - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
The Feasibility of Radiotherapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Cuttino, Laurie , McCall, Linda , Kubicky, C , Ballman, Karla ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019 Abstract - Secondary Endpoint - Primary Analysis - Prevention - Z11102
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103
The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761 D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761
Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715) Dao, Dyda , Zelma, Tyler , Jatoi, Aminah , Freedman, Rachel ... - ASCO - J Clin Oncol - 2018 Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151715 , C8541 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741 , N89-30-52 , N9831
Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance) DeBoer, Rebecca , Mulkey, Flora , Koval, Gregory , Wetzler, Meir ... - EHA - Haematologica - 2014 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001 , CALGB-9665
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657) Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657) Demichele, A. , Yau, C. , Zhu, J. , Wuhfkuhle, J. , Lenburg, M. E. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
Hypothetical double-consent design intervention Demmy, T. L. , Kohman, L. J. ... - CTAS - - 2010 Abstract - No-Endpoint Endpoint - Primary Analysis - Respiratory - CALGB-30102 , CALGB-9334
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102
Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - NCCTG-N0723
Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013 Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087
Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality Assurance Review of ACOSOG Z-4032 Dipetrillo, T. A. , Heron, D. E. , Landreneau, R. J. , Logan, D. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials Dressler, L. G. , Deal, A. M. , Watson, D. , Hollis, D. , Owzar, K. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Health Outcome - CALGB-40101 , CALGB-50303 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401
N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM) Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM) Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901 Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901
Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Dueck, A. C. , Mendoza, T. R. , Mitchell, S. A. , Reeve, B. B. ... - - J. Clin. Oncol. - 2012 Abstract - No-Endpoint Endpoint - Primary Analysis - Health Outcome - Comprehensive
Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. Dueck, A. , Sargent, D. , Novotny, P. , Decker, P. , Nelson, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - N0591
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - N1048
Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer) Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031
Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401
CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer. Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203
CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203
Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304 Edelman, M. J. , Hodgson, L. D. , Wang, X. , Christenson, R. H. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304
Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203 Edelman, M. J. , Watson, D. M. , Wang, X. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203
Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance) Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801
Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011 Abstract - Primary Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - N063D , ALTTO
Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202
Mutations in genes associated with familial predisposition to myeloid neoplasms:their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance) Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202
Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665
MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 ,
